Targeting the PI3K/Akt/mTOR pathway in estrogen-receptor positive HER2 negative advanced breast cancer

Recently many therapeutic classes have emerged in advanced hormone receptor-positive breast cancer, which is the leading cause of cancer death in women. In absence of visceral crisis, treatment relies on endocrine therapy combined with cyclin dependent kinase 4 and 6 inhibitor. Many mechanisms lead...

Descripción completa

Detalles Bibliográficos
Autores principales: du Rusquec, Pauline, Blonz, Cyriac, Frenel, Jean Sebastien, Campone, Mario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7388095/
https://www.ncbi.nlm.nih.gov/pubmed/32782489
http://dx.doi.org/10.1177/1758835920940939

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7388095/
https://www.ncbi.nlm.nih.gov/pubmed/32782489
http://dx.doi.org/10.1177/1758835920940939

Ejemplares similares